CEA, CYFRA21-1 and SCC in non-small cell lung cancer

Moro, D.; Villemain, D.; Vuillez, Jean‐Philippe; DeLord, Corinne; Brambilla, Christian

doi:10.1016/0169-5002(95)00485-8

Cited by 98 publications

(91 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CA125 is used mainly for ovarian cancer screening and diagnosis (23,24), whereas CEA is used for the diagnosis and prognosis of several types of cancer, including colon cancer (25,26). Both CEA and CA125 were useful for monitoring recurrence and evaluating prognosis in NSCLCs but only performed moderately in diagnosing NSCLCs (27)(28)(29)(30)(31)(32)(33). We also included Cyfra21-1 because it is useful for the diagnosis of both SCCs and overall NSCLCs.…”

Section: Discussionmentioning

confidence: 99%

Isocitrate Dehydrogenase 1 Is a Novel Plasma Biomarker for the Diagnosis of Non–Small Cell Lung Cancer

Sun

Chen

Tan

et al. 2013

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: Effective biomarkers for the diagnosis of non-small cell lung cancer (NSCLC) are needed. We previously showed that isocitrate dehydrogenase 1 (IDH1) is significantly increased in NSCLC tumors. This study aimed to examine the plasma levels of IDH1 in a large patient population to evaluate its effectiveness in NSCLC diagnosis.Experimental Design: The plasma levels of IDH1, CA125, Cyfra21-1, and CEA were assayed by ELISA. Blood samples were obtained from 1,422 participants (943 patients with NSCLC and 479 healthy controls). The samples were randomly divided into a training set and a test set. Receiver operating characteristic and binary logistic regression analyses were applied to evaluate diagnostic efficacy and establish diagnostic mathematical models.Results: Plasma IDH1 levels were significantly higher in patients with NSCLCs than in healthy controls (P < 0.001). The diagnostic use of IDH1 in lung adenocarcinoma [area under curve (AUC): 0.858 and 0.810; sensitivity: 77.1% and 76.2%; specificity: 82.9% and 76.6%; in the training set and test set, respectively] was significantly greater than that of CA125, Cyfra21-1, or CEA (P < 0.001). The model combining IDH1 with CEA, CA125, and Cyfra21-1 was more effective for lung adenocarcinoma diagnosis than IDH1 alone (sensitivity and specificity in the training set: 75.8%, 89.6%; test set: 86.3%, 70.7%). In addition, the plasma levels of IDH1 could contribute to the diagnostic model of lung squamous cell carcinoma.Conclusions: IDH1 can be used as a plasma biomarker for the diagnosis of NSCLCs, particularly lung adenocarcinoma, with relatively high sensitivity and specificity.

show abstract

Section: Discussionmentioning

confidence: 99%

Isocitrate Dehydrogenase 1 Is a Novel Plasma Biomarker for the Diagnosis of Non–Small Cell Lung Cancer

Sun

Chen

Tan

et al. 2013

Clinical Cancer Research

View full text Add to dashboard Cite

show abstract

“…Carcinoembryonic antigen (CEA), a glycoprotein first described in 1965 by Gold and Freedman [1], is one of the most widely used tumor makers, and is used in the clinical diagnosis of breast cancer [2][3][4], colon cancer [5][6][7], lung cancer [8,9] and ovarian carcinoma [10]. CEA level in serum is also related to the state of the tumor, so it can be used as a marker to directly evaluate curative effects, recrudescence, and metastasis.…”

Section: Introductionmentioning

confidence: 99%

Quantitative Immunochromatographic Strip Biosensor for the Detection of Carcinoembryonic Antigen Tumor Biomarker in Human Plasma

Zeng¹,

Mao²,

Xu³

et al. 2009

Am. J. Biomed. Sci.

View full text Add to dashboard Cite

Combining the unique optical properties of gold nanoparticle (Au-NP) and the antibody-antigen specific molecular recognition, a quantitative immunochromatographic strip biosensor (QISB) in connection with a portable strip reader was developed for the detection of carcinoembryonic antigen (CEA) tumor biomarker in human plasma. The test is based on the principle of sandwich-type immunreaction on the lateral flow test strip. The polyclonal antibody (Ab) and Au-NP labeled monoclonal Ab are employed to identify CEA specifically. The quantitative detection of CEA was realized by recording the optical intensities of the produced red bands in the strip biosensor with the portable strip reader. The biosensor fabrication and assay parameters (e.g. membrane sources, the concentration of polyclonal Ab in the test zone, the amount of Au-NP-anti-CEA conjugates and the components of running buffer) that govern the sensitivity and reproducibility of the biosensor were optimized. Under optimal conditions, the response of the QISB is linear in the range of 10 -200 ng mL -1 with a detection limit of 5 ng mL -1 (S/N = 3) in association with a 10-min assay time. The biosensor has also been successfully applied for the detection of CEA in human serum sample. The QISB thus provides a rapid, sensitive, low cost clinical diagnosis tool for the detection of protein biomarkers in biological samples.

show abstract

“…By analysing the different prognostic studies (Ebert et al, 1993(Ebert et al, , 1997Pujol et al, 1993aPujol et al, , 1996Pujol et al, , 2001aGiovanella et al, 1995;Moro et al, 1995;Paesmans et al, 1995a;Wieskopf et al, 1995;Szturmowicz et al, 1996;Brechot et al, 1997;Hamzaoui et al, 1997;Takei et al, 1997;Hirashima et al, 1998;Niklinski et al, 1998;Nisman et al, 1998Nisman et al, , 1999Foa et al, 1999;Kashiwabara et al, 2000;Buccheri et al, 2003), one can observe that there are some uncertainties regarding the exact hazard ratio of risk of death associated with a high serum CYFRA 21-1 level insofar as the estimated values range from 1.05 (Moro et al, 1995) to 2.8 (Wieskopf et al, 1995). This discrepancy is puzzling and might reflect both the relatively small size of the studies and the inconstancy of co-variables introduced in the proportional hazards model.…”

mentioning

confidence: 99%

CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patients

Molinier

Ébert³

et al. 2004

Br J Cancer

165

123

View full text Add to dashboard Cite

The purpose of this study was to determine the prognostic significance of a high pretreatment serum CYFRA 21-1 level (a cytokeratin 19 fragment) adjusted for the effects of well-known co-variables in non-small-cell lung cancer (NSCLC). This meta-analysis based on individual updated data gathered comprehensive databases from published or unpublished controlled studies dealing with the prognostic effect of serum CYFRA 21-1 level at presentation in NSCLC of any stage (nine institutions, 2063 patients). Multivariate regression was carried out with the Cox model. The proportional hazard assumption for each of the selected variables retained in the final model was originally checked by log minus log plots baseline hazard ratio. The follow-up ranged from 25 to 78 months. A total of 1616 events were recorded. In the multivariate analysis performed at the 1-year end point, a high pretreatment CYFRA 21-1 level was an unfavourable prognostic determinant in all centres except one (Hazard ratio (95% confidence interval): 1.88 (1.64 -2.15), Po10 À4 ). Other significant variables were stage of the disease, age and performance status. Within the first 18 months, the procedure disclosed a nearly similar hazard ratio for patients having a high pretreatment serum CYFRA 21-1 level (1.62 (1.42 -1.86), Po10 À4 ). For patients who did not undergo surgery, the hazard ratio during the first year of follow-up was 1.78 (1.54 -2.07), Po10À4 . Finally, in the surgically treated population, at the 2-year end point, a high pretreatment CYFRA 21-1 and a locally advanced stage remained unfavourable prognostic determinants. In conclusion CYFRA 21-1 might be regarded as a putative co-variable in analysing NSCLC outcome inasmuch as a high serum level is a significant determinant of poor prognosis whatever the planned treatment.

show abstract

CEA, CYFRA21-1 and SCC in non-small cell lung cancer

Cited by 98 publications

References 9 publications

Isocitrate Dehydrogenase 1 Is a Novel Plasma Biomarker for the Diagnosis of Non–Small Cell Lung Cancer

Isocitrate Dehydrogenase 1 Is a Novel Plasma Biomarker for the Diagnosis of Non–Small Cell Lung Cancer

Quantitative Immunochromatographic Strip Biosensor for the Detection of Carcinoembryonic Antigen Tumor Biomarker in Human Plasma

CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patients

Contact Info

Product

Resources

About